CTA
FATE icon

Carillon Tower Advisers’s Fate Therapeutics FATE Stock Holding History

Carillon Tower Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$17.3M Buy
+190,482
New +$11.8M 0.11% 271

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Carillon Tower Advisers's FATE Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in Fate Therapeutics (FATE) in Q4 2020: 190,482 shares worth $17.3M. The stake represents 0.11% of the portfolio and ranks #271 among its holdings.

248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • Carillon Tower Advisers held 190,482 shares of Fate Therapeutics worth $17.3M as of Q4 2020.
  • Fate Therapeutics was a new Carillon Tower Advisers position in Q4 2020.
  • Fate Therapeutics made up 0.11% of Carillon Tower Advisers's portfolio in Q4 2020, its #271 holding.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.